Overview Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours Status: Completed Trial end date: 2019-01-16 Target enrollment: Participant gender: Summary The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus. Phase: Phase 1 Details Lead Sponsor: Canadian Cancer Trials GroupCollaborator: PfizerTreatments: EverolimusSirolimusVinblastine